Expert Commentary: The Safety of Fibrates in Lipid-Lowering Therapy
Open Access
- 19 March 2007
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 99 (6) , S19-S21
- https://doi.org/10.1016/j.amjcard.2006.11.017
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2006
- PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosisJournal of Lipid Research, 2004
- Fatty Acids, Eicosanoids, and Hypolipidemic Agents Identified as Ligands of Peroxisome Proliferator-Activated Receptors by Coactivator-Dependent Receptor Ligand AssayMolecular Endocrinology, 1997
- WHO clofibrate/cholesterol trial: clarificationsThe Lancet, 1992
- Treatment of hypercholesterolaemia with fenofibrate: a reviewCurrent Medical Research and Opinion, 1989
- Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Heart, 1978
- The Biochemical, Clinical, and Genetic Features of Type III HyperlipoproteinemiaAnnals of Internal Medicine, 1975
- On the lipoprotein abnormality in type III hyperlipoproteinemiaJournal of Clinical Investigation, 1971
- Effects of hyperlipoproteinemias and their treatment on the peripheral circulationJournal of Clinical Investigation, 1970